Study of Bexarotene in Patients With Acute Myeloid Leukemia
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Bexarotene may be useful in the treatment of Acute Myeloid Leukemia (AML). This is the first
study on the use of bexarotene to treat patients with AML. The main purpose of this study is
to establish the proper dose of bexarotene when used to treat AML. The side effect profile of
bexarotene in patients with AML will also be explored.
Phase:
Phase 1
Details
Lead Sponsor:
Abramson Cancer Center of the University of Pennsylvania